Literature DB >> 12514409

Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.

Silvia Ratto-Kim1, Lawrence D Loomis-Price, Naomi Aronson, Janelle Grimes, Cristin Hill, Chevelle Williams, Raphaelle El Habib, Deborah L Birx, Jerome H Kim.   

Abstract

In this study, we investigated the CD4 T-helper response induced by ALVAC-HIV(vCP205) +/- rgp160MN/LAI-2 using a series of 15 overlapping amino acid peptides spanning the entire gp160MN/LAI-2 antigen. CD4 Env-specific T-cell lines were established from three groups of HIV-1-negative HIV vaccine recipients: vCP205 + gp160MN/LAI-2, vCP205 only, and gp160MN/LAI-2 only. CD4 Env-specific T-cell lines established from individuals who received the prime-boost vCP205 + rgp160MN/LAI-2 generated strong and broad T-helper responses scattered across the Env sequence, whereas Env-specific T-cell lines from individuals receiving the vCP205 vaccine alone generated reactivity to only a few peptides. CD4 -specific T-cell lines were also established from HIV-1-infected individuals and demonstrated poor reactogenicity to Env peptides in both breadth and amplitude of response. These results highlight the complexity of major histocompatibility complex class II presentation and CD4 antigen-specific reactivity, emphasizing the need to better understand these crucial T-helper cell responses in the setting of HIV infection and HIV vaccine development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12514409     DOI: 10.1097/00126334-200301010-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Authors:  Mark S de Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M Paris; Jaranit Kaewkungwal; Nelson L Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R Currier; Jerome H Kim
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

Review 2.  Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Authors:  Monica Vaccari; Poonam Poonam; Genoveffa Franchini
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

Review 3.  HIV vaccines in infants and children.

Authors:  John S Lambert
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes.

Authors:  A Reyes-Sandoval; J C Fitzgerald; R Grant; S Roy; Z Q Xiang; Y Li; G P Gao; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.

Authors:  Gilles Pialoux; Romina P Quercia; Hanne Gahery; Nathalie Daniel; Laurence Slama; Pierre-Marie Girard; Philippe Bonnard; Willy Rozenbaum; Véronique Schneider; Dominique Salmon; Jean-Gérard Guillet
Journal:  Clin Vaccine Immunol       Date:  2008-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.